Neuropathology and Neuropharmacology of Monoaminergic Systems
Rona R Ramsay, Philippe De Deurwaerdère
Philippe De Deurwaerdère (firstname.lastname@example.org)
Issue: Xjenza Online Vol. 2 Iss. 2 - October 2014
The third EU COST Action CM1103 Structure-based drug design for diagnosis and treatment of neurological diseases: dissecting and modulating complex function in the monoaminergic systems of the brain" Annual Conference entitled Neu- ropathology and Neuropharmacology of Monoaminergic Systems" was hosted by the University of Bordeaux, France on 8-10 October 2014. The conference, or- ganized by Prof. De Deurwaerdere, was supported by COST (European Cooperation in Science and Technology) and LABEX (LABEX Brain, University of Bordeaux). The program took the form of a three-day meeting, comprising a series of French and international invited talks and breakout sessions designed to identify key gaps in current knowledge and potential future research questions. The aims of this Conference were two-fold: 1. To identify the current state-of-the-art in the understanding of the pathological mechanisms that contribute to different neuropsychiatric disorders, and to what extent, monoamines a multi-target drugs and/or other interventions might prevent these changes. 2. To identify specic areas of research where informa- tion is sparse but which are likely to yield data that will impact on future strategies to treat neurodegenerative disorders.